Halozyme Therapeutics reported earnings of $ 2.39 per HALO share on Nov 5, 2026, beating analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | $ 2.30 |
| Earnings Per Share (Surprise) | $ 2.39 (+$ 0.09) |
| Last Year's EPS | $ 1.03 |
| EPS YoY Change |
Out of the last 98 earnings reporting periods, Halozyme Therapeutics beat analysts’ expectations 47 times and fell short of expectations 37 time(s). Halozyme Therapeutics reported earnings per share of $ 2.39 in the last report surpassing an estimated EPS of $ 2.30 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | $ 2.30 | $ 2.39 | $ 1.72 | |
| Aug 6, 2026 | $ 1.79 | $ 2.28 | $ 1.54 | |
| May 11, 2026 | $ 1.55 | $ 1.60 | $ 1.11 | |
| Feb 17, 2026 | $ 2.15 | -$ 0.24 | $ 1.26 | |
| Nov 3, 2025 | $ 1.63 | $ 1.72 | $ 1.27 | |
| Aug 5, 2025 | $ 1.23 | $ 1.54 | $ 0.91 | |
| May 6, 2025 | $ 0.95 | $ 1.11 | $ 0.79 | |
| Feb 18, 2025 | $ 1.17 | $ 1.26 | $ 0.82 | |
| Oct 31, 2024 | $ 0.98 | $ 1.27 | $ 0.75 | |
| Aug 6, 2024 | $ 0.76 | $ 0.91 | $ 0.74 | |
| May 7, 2024 | $ 0.70 | $ 0.79 | $ 0.47 | |
| Feb 20, 2024 | $ 0.83 | $ 0.82 | $ 0.48 | |
| Nov 6, 2023 | $ 0.71 | $ 0.75 | $ 0.74 | |
| Aug 8, 2023 | $ 0.63 | $ 0.74 | $ 0.53 | |
| May 9, 2023 | $ 0.48 | $ 0.47 | $ 0.47 | |
| Feb 21, 2023 | $ 0.47 | $ 0.48 | $ 0.42 | |
| Nov 8, 2022 | $ 0.51 | $ 0.74 | $ 0.55 | |
| Aug 9, 2022 | $ 0.50 | $ 0.53 | $ 0.66 | |
| May 10, 2022 | $ 0.49 | $ 0.47 | $ 0.20 | |
| Feb 22, 2022 | $ 0.41 | $ 0.42 | $ 0.50 |
Halozyme Therapeutics’s stock was trading at $ 130.34 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, HALO’s price decreased to $ 103.63 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | $ 2.39 | $ 130.34 | $ 103.63 | |
| Aug 6, 2026 | $ 2.28 | $ 83.59 | $ 103.12 | |
| May 11, 2026 | $ 1.60 | $ 64.12 | $ 70.93 | |
| Feb 17, 2026 | -$ 0.24 | $ 79.44 | $ 73.23 | |
| Nov 3, 2025 | $ 1.72 | $ 65.19 | $ 68.05 | |
| Aug 5, 2025 | $ 1.54 | $ 59.99 | $ 62.32 | |
| May 6, 2025 | $ 1.11 | $ 60.62 | $ 70.14 | |
| Feb 18, 2025 | $ 1.26 | $ 58.29 | $ 57.77 | |
| Oct 31, 2024 | $ 1.27 | $ 50.59 | $ 57.15 | |
| Aug 6, 2024 | $ 0.91 | $ 52.11 | $ 54.12 | |
| May 7, 2024 | $ 0.79 | $ 40.86 | $ 42.01 | |
| Feb 20, 2024 | $ 0.82 | $ 36.10 | $ 38.36 | |
| Nov 6, 2023 | $ 0.75 | $ 35.58 | $ 38.80 | |
| Aug 8, 2023 | $ 0.74 | $ 42.01 | $ 42.63 | |
| May 9, 2023 | $ 0.47 | $ 30.28 | $ 34.49 | |
| Feb 21, 2023 | $ 0.48 | $ 50.03 | $ 50.08 | |
| Nov 8, 2022 | $ 0.74 | $ 46.28 | $ 49.71 | |
| Aug 9, 2022 | $ 0.53 | $ 45.04 | $ 44.10 | |
| May 10, 2022 | $ 0.47 | $ 37.35 | $ 38.58 | |
| Feb 22, 2022 | $ 0.42 | $ 32.72 | $ 33.74 |
Halozyme Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Halozyme Therapeutics beat analysts’ expectations during the last earnings period by
